Fabrazyme (agalsidase beta) + Fabrazyme (agalsidase beta)
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fabry Disease
Conditions
Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Trial Timeline
Dec 1, 2002 → Aug 1, 2003
NCT ID
NCT00837824About Fabrazyme (agalsidase beta) + Fabrazyme (agalsidase beta)
Fabrazyme (agalsidase beta) + Fabrazyme (agalsidase beta) is a phase 2 stage product being developed by Sanofi for Fabry Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT00837824. Target conditions include Fabry Disease, Chronic Kidney Disease, Stage IV (Severe).
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00837824 | Phase 2 | Terminated |
Competing Products
20 competing products in Fabry Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lucerastat | Idorsia | Phase 3 | 72 |
| Fabrazyme (agalsidase beta) | Sanofi | Phase 2 | 51 |
| Venglustat (GZ402671) + Placebo | Sanofi | Phase 3 | 76 |
| agalsidase beta | Sanofi | Approved | 84 |
| Tropicamide | Sanofi | Pre-clinical | 22 |
| Fabrazyme (agalsidase beta) | Sanofi | Approved | 84 |
| agalsidase beta | Sanofi | Approved | 84 |
| AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + Fexofenadine | Sanofi | Approved | 84 |
| Gabapentin + placebo | Sanofi | Phase 2 | 51 |
| Agalsidase beta | Sanofi | Approved | 84 |
| GZ/SAR402671 | Sanofi | Phase 2 | 51 |
| agalsidase beta (GZ419828) + agalsidase alfa | Sanofi | Approved | 84 |
| Fabrazyme (agalsidase beta) | Sanofi | Phase 3 | 76 |
| Venglustat (GZ402671) + Agalsidase alfa + Agalsidase beta (GZ419828) + Migalastat | Sanofi | Phase 3 | 76 |
| Iohexol | Sanofi | Phase 1 | 32 |
| GZ/SAR402671 | Sanofi | Phase 2 | 51 |
| Fabrazyme (agalsidase beta) | Sanofi | Phase 2 | 51 |
| Agalsidase beta | Sanofi | Approved | 84 |
| Fabrazyme (agalsidase beta) + Placebo | Sanofi | Approved | 84 |
| Agalsidase beta + Agalsidase beta | Sanofi | Phase 3 | 76 |